Welch Capital Partners LLC NY Trims Stake in Humana Inc. (NYSE:HUM)

Key Points

• Welch Capital Partners LLC NY decreased its holdings in Humana Inc. by 23.2%, selling 6,395 shares and now owns 21,203 shares, valued at approximately $5.61 million.
• Institutional investors own 92.38% of Humana's stock, indicating significant institutional interest in the company.
• Humana reported quarterly earnings with $6.27 EPS, missing consensus estimates, but achieved a revenue of $32.39 billion, exceeding expectations by $540 million.

Welch Capital Partners LLC NY cut its holdings in Humana Inc. (NYSE:HUM - Free Report) by 23.2% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 21,203 shares of the insurance provider's stock after selling 6,395 shares during the quarter. Humana accounts for approximately 1.3% of Welch Capital Partners LLC NY's holdings, making the stock its 9th largest position. Welch Capital Partners LLC NY's holdings in Humana were worth $5,610,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Deutsche Bank AG lifted its holdings in shares of Humana by 18.2% during the 4th quarter. Deutsche Bank AG now owns 631,371 shares of the insurance provider's stock valued at $160,185,000 after buying an additional 97,071 shares during the period. Janney Montgomery Scott LLC purchased a new stake in Humana during the first quarter valued at $1,309,000. Fred Alger Management LLC bought a new position in Humana in the fourth quarter valued at about $451,000. Clearline Capital LP purchased a new position in Humana in the fourth quarter worth about $1,102,000. Finally, Envestnet Asset Management Inc. grew its stake in shares of Humana by 2.4% during the 1st quarter. Envestnet Asset Management Inc. now owns 125,684 shares of the insurance provider's stock valued at $33,256,000 after purchasing an additional 2,950 shares during the period. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on HUM shares. Cantor Fitzgerald reiterated a "neutral" rating and issued a $290.00 price objective on shares of Humana in a research note on Thursday, May 1st. Truist Financial decreased their price target on shares of Humana from $280.00 to $260.00 and set a "hold" rating on the stock in a research report on Wednesday, July 16th. Oppenheimer lifted their price target on shares of Humana from $300.00 to $310.00 and gave the stock an "outperform" rating in a research note on Thursday, May 1st. Raymond James Financial upgraded Humana from a "market perform" rating to an "outperform" rating and set a $315.00 price objective for the company in a research note on Thursday, May 1st. Finally, Barclays set a $275.00 target price on Humana and gave the stock an "equal weight" rating in a report on Thursday, July 31st. Seventeen investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $281.62.

Humana Price Performance

HUM traded down $0.66 during trading on Thursday, hitting $255.96. 850,384 shares of the company traded hands, compared to its average volume of 2,015,970. The company has a current ratio of 1.95, a quick ratio of 1.95 and a debt-to-equity ratio of 0.69. The company has a market cap of $30.78 billion, a PE ratio of 19.64, a P/E/G ratio of 1.51 and a beta of 0.44. The stock's 50-day simple moving average is $237.21 and its two-hundred day simple moving average is $254.50. Humana Inc. has a 1 year low of $206.87 and a 1 year high of $382.72.

Humana (NYSE:HUM - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The insurance provider reported $6.27 EPS for the quarter, missing the consensus estimate of $6.32 by ($0.05). The company had revenue of $32.39 billion for the quarter, compared to the consensus estimate of $31.85 billion. Humana had a net margin of 1.28% and a return on equity of 13.67%. The firm's revenue for the quarter was up 9.6% on a year-over-year basis. During the same period last year, the company earned $6.96 EPS. As a group, sell-side analysts anticipate that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.